| |
Monday, October 17, 2022 | 11am ET / 8am PT Given the wide array of post transcriptional and post translational regulatory processes that govern cellular dynamics, additional omics types are needed to capture a more comprehensive understanding of the molecular landscape of a tumor. Register now to learn more.
|
|
Today's Big NewsOct 12, 2022 |
| By James Waldron Merck & Co. had a busy morning signing off on licensing deals for midstage assets. The Big Pharma not only confirmed it would push ahead with developing a therapeutic cancer vaccine with mRNA leader Moderna but also signed up to collaborate on its schizophrenia treatment with Royalty Pharma. |
|
|
|
By Gabrielle Masson Bayer subsidiary Vividion Therapeutics has partnered with Tavros Therapeutics to find targets for hard-to-treat diseases, paying out $17.5 million cash and offering the biotech up to $912.5 million in biobucks. |
By Nick Paul Taylor After kicking the tires on Autolus Therapeutics’ targeting technology, Moderna has decided to pay up for the right to use the binders in an mRNA therapy. The exercising of the option positions Moderna to use the binders in a candidate against an undisclosed immuno-oncology target. |
By Nick Paul Taylor Sangamo Therapeutics has presented updated preliminary data from its phase 1/2 Fabry disease clinical trial, revealing that recipients of its gene therapy had elevated levels of a key enzyme even after stopping taking the standard of care. |
By Gabrielle Masson CAR-Ts have already changed the treatment landscape when it comes to blood cancers, but getting a cell therapy to market for solid tumors remains tantalizingly out of reach. Now, Inceptor Bio and cell engineering tech company Avectas are taking on the challenge. |
By Max Bayer Ascidian Therapeutics is launching up from the ocean floor with $50 million in series A funds. The company's primary focus is the continued development of its lead asset targeting ABCA4 gene mutations. |
By Andrea Park Ahead of its third-quarter earnings report, Philips steeled investors for less-than-stellar sales and order intake growth, compounded by a pair of non-cash charges for the quarter that together amount to nearly 1.5 billion euros. |
By Dave Muoio More than 2.2 million women of childbearing age live in counties without hospitals, birth centers or other providers offering obstetric care, according to a report published Tuesday. |
By Ben Adams Think of October and you will imagine falling leaves, Halloween and colder nights, but it’s an important month in oncology as it’s also Breast Cancer Awareness Month. And this year, Novartis is looking to boost awareness by tapping personal stories of those living with the disease. |
By Angus Liu As BeiGene gears up for an all-out war against AbbVie and Johnson & Johnson’s Imbruvica, the company has turned in more clinical evidence to show it has the winning BTK inhibitor to fight certain blood cancers. |
By Frank Diamond The U.S. Preventive Services Task Force yesterday recommended extending anxiety screening for children between 8 and 18. Meanwhile, a report by the United Health Foundation underscores just how serious youth mental health problems have become. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we talk about the trend of retail giants getting involved primary care. Also under discussion is our special report spotlighting the important contributions made by people of color across health systems, physicians' offices, health tech and insurance companies. |
|
|---|
|
|
|
Scaling biotechs are at a unique intersection of capital, opportunity and flexibility. And real estate is key to driving business forward. Get answers to six key questions to ensure you have the space and solutions to grow where and when you need to. Learn more.
|
|
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
